If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
372
results.
Updated on
24/10/2026 [08:50:00]
Absstract of: US20260327196A1
Provided herein are compounds, methods and compositions for determining whether a patient has a neurological disease or disorder is provided, comprising detecting the presence of a target protein, or an accumulated mass thereof, for example, amyloid beta protein or phosphorylated tau protein, or an accumulated mass thereof, in a tissue or a sample of the patient. The detecting may comprise contacting the target protein with a compound described herein.
Absstract of: US20260328758A1
Provided is a method for detecting target substances. The method includes a) introducing a sample containing target substances onto a substrate, b) allowing detection probes conjugated with docking strands to specifically bind to the target substances, c) introducing one or more separate strands capable of complementary binding to the docking strands into the docking strands, either the docking strands or the separate strands, or both, are labeled with at least one donor fluorescent substance and at least one acceptor fluorescent substance, and d) measuring fluorescence signals generated by the FRET between the donor fluorescent substance and the acceptor fluorescent substance to identify the target substances.
Absstract of: US20260327309A1
0000 The present disclosure relates to combination therapies comprising immune checkpoint inhibitors and antibodies directed to neurological biomarkers, compositions comprising immune checkpoint inhibitors and antibodies directed to neurological biomarkers, and methods of treatment using such combination therapies and/or compositions.
Absstract of: US20260328785A1
0000 The present invention relates to the field of virology. More specifically, the present invention provides compositions and methods for assessing the severity of and treating severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) or COVID-19. In particular embodiments, a method for treating COVID-19 in a patient comprises the step of administering to the patient an isolated, recombinant antibody or antigen-binding fragment thereof that binds human Resistin.
Absstract of: US20260328784A1
0000 Alpha-Synuclein mutants and uses thereof are disclosed herein. The mutants of the present invention are non-self-aggregating forms of Alpha-Synuclein which make them a suitable candidate for use as substrates in aggregation assay for evaluating the presence of misfolded α-Syn protein. Also disclosed are kits and method for detection of synucleinopathies in individuals, using the mutants of the present invention.
Absstract of: US20260325476A1
0000 Disclosed are methods for inhibiting the progression of neurodegenerative disease. The methods include administering to a patient suffering from such a disease a composition comprising either deuterated linoleic acid or an ester thereof.
Absstract of: US20260328783A1
The present disclosure relates to a biomarker composition for diagnosis of a degenerative brain disease, and more particularly, in an attempt to distinguish between normal people, mild cognitive impairment (MCI) patients, and Alzheimer's disease (AD) patients, provides a biomarker composition that distinguishes between the normal people, mild cognitive impairment (MCI) patients, and Alzheimer's disease (AD) patients by measuring levels of amyloid beta 40 (Aβ40), amyloid beta 42 (Aβ42), brain-derived neurotrophic factor (BDNF), Tau, neuron-specific enolase (NSE), glial fibrillary acidic protein (GFAP), ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), peptidyl-prolyl isomerase (PIN1), collapsing response mediator protein-2 (CRMP2), phospho-Tau231, and olfactory marker protein (OMP) as biomarkers in the blood to identify correlation thereof.
Absstract of: US20260325471A1
Disclosed are methods, systems, compositions, and kits for diagnosing, staging, monitoring, and treating conditions associated with bioenergetic insufficiency in a subject or biological system. The disclosure is grounded in the Unified Theory of Bioenergetic Sufficiency (UTBS), which defines cellular health based on maintaining a Metabolic Sufficiency Ratio (M), the ratio of effective energy generation rate (E) to total energy requirement rate (R), above a critical threshold (M=E/R >M_crit). As well as, Metabolic-Epigenetic-Redox Immune Therapy (MERIT), a new therapeutic class of pharmacological, treat-to-target ketone body therapies for diseases characterized by metabolic, redox, epigenetic, or immune dysregulation.
Absstract of: US20260325651A1
0000 The disclosure relates to lipase modulators, compositions comprising such modulators, and methods of using the same to regulate lipid metabolism, efferocytosis, and/or macrophage function. In certain aspects, the disclosure provides compositions and methods for modulating intracellular lipase activity, lipolysis, inflammatory signaling, membrane remodeling, and/or pro-resolving macrophage polarization, including for treating conditions associated with dysregulated lipid metabolism, impaired efferocytosis, and/or impaired macrophage function. The disclosure also provides in vitro methods for identifying candidate agents that increase macrophage efferocytosis, enhance lipase-associated signaling or activity, increase membrane fluidity, increase receptor clustering or receptor polarization, or promote a pro-resolving macrophage phenotype.
Absstract of: US20260325565A1
Mammals rely on adaptive immunity to protect against infections and tumors, with the thymus playing a crucial role by producing T cells that target infected or cancerous cells. The thymus, however, undergoes functional decline with age, significantly impairing the immune system in the elderly. To investigate reversing this decline, compositions and methods for activation and differentiation of T cell progenitors in extrathymic tissues are disclosed that stimulate production of differentiated T cells. For example, LNP-mediated delivery of mRNAs encoding DLL-1, IL-7, and FLT3L to the liver is shown to create a temporary site for T cell maturation that enhances T cell-mediated immunity in aged mice without causing autoimmunity. This approach facilitates ectopic T cell development from hematopoietic precursors and activates dendritic cells, providing evidence that engineering adaptive immunity in vivo can effectively mitigate immune aging.
Absstract of: US20260325655A1
The present disclosure provides compounds of the formulae herein (e.g., Formula (I)), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, and prodrugs thereof, which bind and/or effect degradation of an RNA target. The present disclosure also provides pharmaceutical compositions and kits comprising the compounds, or pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, or prodrugs thereof, and methods of treating or preventing diseases by administering to a subject in need thereof the compounds, or pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, or prodrugs thereof, or pharmaceutical compositions thereof.
Absstract of: US20260327295A1
The present invention relates to single-domain antibodies (sdAbs) binding C-reactive protein (CRP). In particular, the invention relates to sdAbs that bind CRP within a specific range of an on-rate constant and off-rate constant. The sdAbs of the present invention can associate and dissociate with CRP in a continuous manner. The invention further relates to nucleic acids encoding anti-CRP sdAbs, methods for detecting CRP, methods of treatment and diagnosis making use of the anti-CRP sdAbs, methods for monitoring CRP levels and apparatuses comprising the anti-CRP sdAbs.
Absstract of: US20260327282A1
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Absstract of: US20260327704A1
This invention provides gene expression profiles useful for diagnosing atrial fibrillation in ischemic stroke and for distinguishing atrial fibrillation in ischemic stroke from arterial (large vessel) stroke or embolic stroke of undetermined source (ESUS).
Absstract of: US20260327296A1
0000 The present invention is in the field of transactive response DNA binding protein with a molecular weight of 43 kDa (TARDB or also TDP-43). The invention relates to TDP-43 specific binding molecules, in particular to anti-TDP-43 antibodies or an antigen-binding fragment or a derivative thereof and uses thereof. The present invention provides means and methods to diagnose, prevent, alleviate and/or treat a disease, disorder and/or abnormality associated with TDP-43 aggregates including but not limited to Frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), Chronic Traumatic Encelopathy (CTE), and limbic-predominant age-related TDP-43 encephalopathy (LATE).
Absstract of: US20260327702A1
0000 The present disclosure encompasses embodiments of nucleic acids comprising genetic elements which are useful for the detection of diseased cells.
Absstract of: US20260328782A1
0000 The present disclosure provides methods for monitoring inflammation in ALS and other related diseases. Therapeutic interventions based on the results of monitoring methods are also provided.
Absstract of: US20260328775A1
0000 Provided is a method of efficiently isolating and detecting an antigen molecule from an antigen-antibody complex in a biological sample. Provided is a method of isolating an antigen molecule from a liquid sample comprising an antigen-antibody complex, the method including: a binding step of binding the antibody molecule in the antigen-antibody complex to an antibody-binding protein by applying the liquid sample to a column on which the antigen-binding protein is immobilized; and an elution step of eluting an elution liquid comprising the antigen molecule by applying a buffer liquid to the column to dissociate the antigen molecule in the antigen-antibody complex from the antibody molecule, wherein the buffer liquid is applied to the column while the pH of the buffer liquid decreases in a continuous or stepwise manner in the elution step.
Absstract of: EP4826385A1
The present invention relates to method of determining risk of an inflammatory condition, and/or risk of progression of an inflammatory condition, as well as to compounds for use in these methods.
Absstract of: WO2025016362A1
The present invention relates to the field of biomedicine, in particular, to the use of an intracerebral phosphate homeostasis promoter in cerebral calcification diseases. The intracerebral phosphate homeostasis promoter comprises an agent capable of regulating alternative splicing in an intron of the SLC20A2 gene or an agent targeting astrocytes. In addition, further provided in the present invention are an agent capable of regulating alternative splicing in an intron of the SLC20A2 gene, and the use thereof. Further provided in the present invention are a cerebral calcification model based on alternative splicing in an intron of the human SLC20A2 gene, and a preparation method therefor and the use thereof.
Absstract of: WO2022182949A2
The present disclosure provides biomarkers associated with caveolin-1 peptide therapy in subjects with interstitial lung disease. In particular, the present disclosure describes biomarkers such as MYDGF, soluble RAGE, pSMAD2/3, and PDGFRβ associated with caveolin-1 peptide therapy in subjects with idiopathic pulmonary fibrosis. These biomarkers could be used to determine efficacy, monitoring, and optimal dosing of caveolin-1 peptide therapy in subjects with interstitial lung disease.
Absstract of: US20260318900A1
0000 Disclosed are methods for full morphological labeling of individual neurons from any species or cell type for subsequent cell-delineated protein analysis. These methods, which combines patch-clamp electrophysiology with epitope-preserving magnified analysis of proteome (eMAP), additionally allow for correlation of physiological properties with subcellular protein expression.
Absstract of: US20260315577A1
0000 The present disclosure relates to compositions and methods useful for assessing the hemostatic efficacy in a patient having suffered from intracranial hemorrhage while undergoing an anticoagulation treatment with a factor Xa (fXa) inhibitor. The method can include administering to the patient a fXa derivative that has reduced catalytic activity as compared to the wild-type fXa protein, is capable of binding to the factor Xa inhibitor and cannot assemble into a prothrombinase complex; obtaining a blood sample from the patient following the administration; and measuring an anti-fXa activity in the sample, wherein the anti-fXa activity reflects the hemostatic efficacy in the patient. Once the assessment is made, suitable medical interventions can be implemented.
Absstract of: AU2025249144A1
The present disclosure relates in some aspects to methods of labeling a detection reagent and uses thereof for detecting and diagnosing types of amyloid-related diseases. Also provided herein are methods of treatment comprising selecting a treatment based upon a particular type of amyloid disease.
Nº publicación: AU2025232447A1 15/10/2026
Applicant:
SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INST LIMITED
SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE LIMITED
Absstract of: AU2025232447A1
The present invention relates to methods and products for assessing autophagic flux, and more specifically provides a biochemical functional measure used to quantify autophagic flux in sub-populations of blood cells. The present invention also provides lysosomal system markers for use in the methods described herein, systems for assessing autophagic flux, methods of identifying markers indicative of autophagic flux, and methods of treating subjects found to be suffering from, or susceptible to, a disease, condition or state associated with autophagic flux dysfunction using the methods described herein.
BOPI
Electronic site
